Plain-English translation of NCT06212674 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a combined single-stage procedure that treats two heart problems at once in patients who have recently experienced a stroke caused by atrial fibrillation (irregular heartbeat). The procedure involves two interventions: one that isolates the pulmonary veins to restore normal heart rhythm, and another that implants a small device to block the left atrial appendage (a pouch in the heart where blood clots can form). The study compares this combined approach to either the device implant alone or to ongoing blood-thinning medication.
Many patients who have a stroke from irregular heartbeat need both rhythm control and blood clot prevention, but current treatment often requires multiple separate procedures or relies on long-term medication that may not be suitable for everyone. This trial aims to see whether performing both treatments together in one procedure is safe, effective, and may reduce the burden and cost of care for these high-risk patients.
You likely qualify if…
You likely don't qualify if…
If you are enrolled, you will be randomly assigned to one of three groups: receiving the combined procedure (heart rhythm isolation plus clot-blocking device implant in one operation), receiving only the clot-blocking device implant, or continuing on blood-thinning medication alone. You will undergo heart imaging (including an ultrasound of your heart from inside your throat) before the procedure to confirm your heart anatomy is suitable. The combined procedure group will have a single operation using a catheter inserted through a blood vessel, while the other two groups will receive their assigned treatment and be monitored over time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Poland